MXPA04001828A - Protocolos terapeuticos mejorados. - Google Patents

Protocolos terapeuticos mejorados.

Info

Publication number
MXPA04001828A
MXPA04001828A MXPA04001828A MXPA04001828A MXPA04001828A MX PA04001828 A MXPA04001828 A MX PA04001828A MX PA04001828 A MXPA04001828 A MX PA04001828A MX PA04001828 A MXPA04001828 A MX PA04001828A MX PA04001828 A MXPA04001828 A MX PA04001828A
Authority
MX
Mexico
Prior art keywords
dox
dose
day
chemotherapeutic agent
hydox
Prior art date
Application number
MXPA04001828A
Other languages
English (en)
Spanish (es)
Inventor
Mark Fox Richard
Original Assignee
Meditech Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7302A external-priority patent/AUPR730201A0/en
Priority claimed from AUPR9504A external-priority patent/AUPR950401A0/en
Application filed by Meditech Res Ltd filed Critical Meditech Res Ltd
Publication of MXPA04001828A publication Critical patent/MXPA04001828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04001828A 2001-08-27 2002-08-27 Protocolos terapeuticos mejorados. MXPA04001828A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR7302A AUPR730201A0 (en) 2001-08-27 2001-08-27 Preventive treatment for toxic side-effects caused by chemotherapeutic agents
AUPR9504A AUPR950401A0 (en) 2001-12-13 2001-12-13 Methods for treatment
PCT/AU2002/001160 WO2003018062A1 (en) 2001-08-27 2002-08-27 Improved therapeutic protocols

Publications (1)

Publication Number Publication Date
MXPA04001828A true MXPA04001828A (es) 2005-03-07

Family

ID=25646785

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001828A MXPA04001828A (es) 2001-08-27 2002-08-27 Protocolos terapeuticos mejorados.

Country Status (7)

Country Link
US (2) US20050042303A1 (https=)
EP (1) EP1427447A4 (https=)
JP (1) JP2005505540A (https=)
CN (1) CN1578677A (https=)
CA (1) CA2458856C (https=)
MX (1) MXPA04001828A (https=)
WO (1) WO2003018062A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
JP5465431B2 (ja) * 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンを用いる治療プロトコル
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
WO2007028196A1 (en) * 2005-09-07 2007-03-15 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20100249064A1 (en) * 2007-09-07 2010-09-30 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2832309B1 (en) 2013-07-31 2018-03-07 Biedermann Technologies GmbH & Co. KG Implant for bones or vertebrae with self-constrained flexibility
JP2020153712A (ja) * 2019-03-18 2020-09-24 ソニーセミコンダクタソリューションズ株式会社 電流生成回路および測距システム

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US410452A (en) * 1889-09-03 Liam wiiarton
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4665107A (en) * 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
WO1998017320A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU718451B2 (en) * 1995-09-14 2000-04-13 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
WO1998029125A1 (fr) * 1996-12-27 1998-07-09 Seikagaku Corporation Remedes contre des troubles de la vessie
DE69809892T2 (de) * 1997-04-04 2003-08-28 Fidia Advanced Biopolymers S.R.L., Brindisi N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
DK1140198T3 (da) * 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ATE312076T1 (de) * 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
JP5465431B2 (ja) * 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンを用いる治療プロトコル
WO2007028196A1 (en) * 2005-09-07 2007-03-15 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Also Published As

Publication number Publication date
WO2003018062A1 (en) 2003-03-06
EP1427447A4 (en) 2007-05-23
CN1578677A (zh) 2005-02-09
US20050042303A1 (en) 2005-02-24
US20090306012A1 (en) 2009-12-10
EP1427447A1 (en) 2004-06-16
JP2005505540A (ja) 2005-02-24
CA2458856A1 (en) 2003-03-06
CA2458856C (en) 2011-02-15

Similar Documents

Publication Publication Date Title
US20090306012A1 (en) Therapeutic protocols
US12403119B2 (en) Treating lymphomas
EP2307041B1 (en) Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment
EP4233870A2 (en) Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
DE60216305T2 (de) Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
JP2012162569A (ja) 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン
US20150265648A1 (en) Hyaluronan as a chemo-sensitizer in the treatment of cancer
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
Taylor et al. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer
Franiak-Pietryga et al. Maltotriose-modified poly (propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
Guo et al. Bacterial particles retard tumor growth as a novel vascular disrupting agent
Ginopoulos et al. A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb–IV non-small cell lung cancer (NSCLC)
AU2002325635B2 (en) Improved therapeutic protocols
AU2002325635A1 (en) Improved therapeutic protocols
US8236354B1 (en) Use of immunomodulators for the treatment of cancer
US8338383B1 (en) Use of immunomodulators for the treatment of cancer
AU760404B2 (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
GEORGE et al. The prognosis for patients with metastatic renal cell carcinoma (RCC) is poor.
George et al. HORMONE THERAPY

Legal Events

Date Code Title Description
FA Abandonment or withdrawal